Modality
Peptide
MOA
SGLT2i
Target
AHR
Pathway
Fibrosis
Urothelial CaCKD
Development Pipeline
Preclinical
~Feb 2017
→ ~May 2018
Phase 1
Aug 2018
→ Nov 2030
Phase 1Current
NCT08624992
1,656 pts·CKD
2018-08→2030-11·Terminated
1,656 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-11-014.6y awayPh2 Data· CKD
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Termina…
Catalysts
Ph2 Data
2030-11-01 · 4.6y away
CKD
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08624992 | Phase 1/2 | CKD | Terminated | 1656 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR |